For Immediate Release
Contact: Jeanne Thomson
847.836.3330
jthomson@logica3.com
Innovative Technology Company Selects Logica3 to Design Inaugural Annual Report
West Dundee, IL—February 27, 2003—CTI Molecular Imaging, Inc., a leading supplier of products and services for the positron emission tomography (PET) market, selected Logica3 to design and create its first annual report. CTI consummated its initial public offering (IPO) in June 2002, selling more than 11 million shares of common stock with net proceeds of over $170 million.
The annual report theme, “What's Next?,” reinforces CTI's progressive record of developing breakthrough diagnostic imaging technologies used in the detection and diagnosis of cancer, neurological disorders and cardiac disease. During its 18-year history, CTI has consistently pioneered the key advances in the PET industry, and is poised to continue its leadership role in this rapidly evolving market.
“We wanted our first annual report to set us apart from other medical technology companies and to attract attention from investors,” said Michael Lawless, Senior Director of Investor Relations for CTI. “Logica3 did an excellent job of developing a novel concept for our annual report that captured our corporate mission, our rich history of innovation, and our large market opportunity.”
“Logica3 was instrumental in all phases of the development process, from the initial theme and design, through the drafting of the narrative, all the way to the meticulous detail they showed at the printer to ensure a perfect final product. We are extremely pleased with the work Logica3 did for us on the annual report and look forward to working with them again on future design projects,” continued Lawless.
“We were honored that CTI selected us to produce their initial annual report,” said Lisa Page, president of Logica3. “Their core technologies are used every day to improve lives and save lives. This, combined with their outstanding financial performance, makes for a very compelling annual report story.”
About CTI
CTI Molecular Imaging, Inc. is a leading supplier of products and services for PET, a diagnostic imaging technology used in the detection and treatment of cancer, neurological disorders and cardiac disease.